{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T21:54:27Z","timestamp":1763330067900,"version":"3.44.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Patient satisfaction with two teriparatide (TPTD) self-injection regimens [once-daily (1\/D)-TPTD and twice-weekly (2\/W)-TPTD] was compared in a randomized crossover study involving patients with osteoporosis at high fracture risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>Questionnaires evaluated overall satisfaction, satisfaction with treatment effectiveness, satisfaction with utility of the self-injection device, and preference for a particular injection regimen after crossover. Quality of life (QOL), visual analogue scale pain scores, and bone mineral density (BMD) were also analyzed. Safety was evaluated based on the incidence and severity of adverse events (AEs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The 1\/D-TPTD and 2\/W-TPTD groups comprised 180 (mean age: 75.9\u2009\u00b1\u20097.3\u00a0years) and 178 (75.4\u2009\u00b1\u20096.9\u00a0years) patients, respectively. After 26\u00a0weeks of treatment, the injection regimens were switched and treatment continued for another 26\u00a0weeks. Significantly higher persistence was observed in the 1\/D-TPTD to 2\/W-TPTD group (p\u2009=\u20090.032). No significant between-group differences in overall satisfaction scores or satisfaction with treatment were observed. Satisfaction with the utility of the injection device was significantly higher with the 2\/W-TPTD regimen (p\u2009&lt;\u20090.05); this regimen was preferred by 69.4% of patients after crossover (p\u2009&lt;\u20090.001). A significant increase in BMD from baseline was observed at the lumbar vertebrae in both groups and at the hip area in the 1\/D-TPTD to 2\/W-TPTD group at 52\u00a0weeks (p\u2009&lt;\u20090.05). Significant improvement in the QOL score was observed in both groups (p\u2009&lt;\u20090.05). No serious AEs were reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Continuation of this study will further clarify patient satisfaction, treatment effects, and tolerability.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00774-025-01586-y","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:31:12Z","timestamp":1739889072000},"page":"284-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Randomized crossover comparison of two teriparatide self-injection regimens for primary osteoporosis: Interim report (end of 52-week treatment) of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06)"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0955-2747","authenticated-orcid":false,"given":"Satoshi","family":"Soen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sakae","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"1586_CR1","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"1586_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s00774-022-01347-1","volume":"40","author":"R Fujita","year":"2022","unstructured":"Fujita R, Endo T, Takahata M, Haraya K, Suzuki H, Oda I, Kanayama M, Asano T, Shigenobu K, Iwata A, Yamada K, Takeuchi H, Ohura H, Yoneoka D, Iwasaki N (2022) Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis. J Bone Miner Metab 40:782\u2013789. https:\/\/doi.org\/10.1007\/s00774-022-01347-1","journal-title":"J Bone Miner Metab"},{"key":"1586_CR3","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00198-019-05052-0","volume":"30","author":"MA van Maren","year":"2019","unstructured":"van Maren MA, Wyers CE, Driessen JHM, Visser JV, de Vries F, van de Wijdeven K, Gevers S, Lems WF, Emmelot-Vonk MH, van den Bergh JPW (2019) Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporos Int 30:1837\u20131844. https:\/\/doi.org\/10.1007\/s00198-019-05052-0","journal-title":"Osteoporos Int"},{"key":"1586_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11657-018-0487-8","volume":"13","author":"M Sato","year":"2018","unstructured":"Sato M, Tsujimoto M, Kajimoto K, Uetake H, Shimoda H, Fujiwara S (2018) Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS). Arch Osteoporos 13:74. https:\/\/doi.org\/10.1007\/s11657-018-0487-8","journal-title":"Arch Osteoporos"},{"key":"1586_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jbspin.2013.05.001","volume":"81","author":"G Rajzbaum","year":"2014","unstructured":"Rajzbaum G, Grados F, Evans D, Liu-Leage S, Petto H, Augendre-Ferrante B (2014) Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study. Joint Bone Spine 81:69\u201375. https:\/\/doi.org\/10.1016\/j.jbspin.2013.05.001","journal-title":"Joint Bone Spine"},{"key":"1586_CR6","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1080\/03007995.2017.1354826","volume":"33","author":"S Soen","year":"2017","unstructured":"Soen S, Fujiwara S, Takayanagi R, Kajimoto K, Tsujimoto M, Kimura S, Sato M, Krege JH, Enomoto H (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Curr Med Res Opin 33:2049\u20132056. https:\/\/doi.org\/10.1080\/03007995.2017.1354826","journal-title":"Curr Med Res Opin"},{"key":"1586_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10457","volume":"5","author":"DT Gold","year":"2021","unstructured":"Gold DT, Weiss R, Beckett T, Deal C, Epstein RS, James AL, Kernaghan JM, Mohseni M, Spiegel M, Vokes T, Roberts J, Bailey T, Wang Y, Williams SA (2021) Abaloparatide real-world patient experience study. JBMR Plus 5:e10457. https:\/\/doi.org\/10.1002\/jbm4.10457","journal-title":"JBMR Plus"},{"key":"1586_CR8","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","volume":"22","author":"DL Kendler","year":"2011","unstructured":"Kendler DL, McClung MR, Freemantle N, Lillestol M, Moffett AH, Borenstein J, Satram-Hoang S, Yang YC, Kaur P, Macarios D, Siddhanti S, Investigators DAPS (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725\u20131735. https:\/\/doi.org\/10.1007\/s00198-010-1378-z","journal-title":"Osteoporos Int"},{"key":"1586_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, Investigators DAPS (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326. https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporos Int"},{"key":"1586_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-011-1620-3","volume":"23","author":"E Barrett-Connor","year":"2012","unstructured":"Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D (2012) Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US\u2122. Osteoporos Int 23:733\u2013741. https:\/\/doi.org\/10.1007\/s00198-011-1620-3","journal-title":"Osteoporos Int"},{"key":"1586_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1472-6874-10-26","volume":"10","author":"D Huas","year":"2010","unstructured":"Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin AF, Cott\u00e9 FE (2010) Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health 10:26","journal-title":"BMC Womens Health"},{"key":"1586_CR12","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00198-019-05111-6","volume":"30","author":"T Sugimoto","year":"2019","unstructured":"Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T (2019) Study of twice-weekly injections of teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. Osteoporos Int 30:2321\u20132331. https:\/\/doi.org\/10.1007\/s00198-019-05111-6","journal-title":"Osteoporos Int"},{"key":"1586_CR13","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1007\/s00774-024-01521-7","volume":"42","author":"S Soen","year":"2024","unstructured":"Soen S, Uemura Y, Tanaka S, Takeuchi Y, Endo N, Takada J, Ikeda S, Iwamoto J, Okimoto N, Tanaka S (2024) A crossover comparison of patient satisfaction with two teriparatide regimens: primary results of the Japanese Osteoporosis Intervention Trial 06 (JOINT-06). J Bone Miner Metab 42:582\u2013590. https:\/\/doi.org\/10.1007\/s00774-024-01521-7","journal-title":"J Bone Miner Metab"},{"key":"1586_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T; Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, Endo N, Gorai I, Shiraki M, Hagino H, Hosoi T, Ohta H, Yoneda T, Tomomitsu T; Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for the Revision of the Diagnostic Criteria for Primary Osteoporosis (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257. https:\/\/doi.org\/10.1007\/s00774-013-0447-8","journal-title":"J Bone Miner Metab"},{"key":"1586_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"key":"1586_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bone.2010.05.022","volume":"47","author":"A Miyauchi","year":"2010","unstructured":"Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493\u2013502. https:\/\/doi.org\/10.1016\/j.bone.2010.05.022","journal-title":"Bone"},{"key":"1586_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s00774-020-01186-y","volume":"39","author":"J Takada","year":"2021","unstructured":"Takada J, Yoshimura T, Uzawa T (2021) Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels. J Bone Miner Metab 39:484\u2013493. https:\/\/doi.org\/10.1007\/s00774-020-01186-y","journal-title":"J Bone Miner Metab"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-025-01586-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-025-01586-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T05:57:43Z","timestamp":1757138263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-025-01586-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1586"],"URL":"https:\/\/doi.org\/10.1007\/s00774-025-01586-y","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"type":"print","value":"0914-8779"},{"type":"electronic","value":"1435-5604"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S Soen has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Mochida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co., Ltd. Y Uemura has received speaking fees from Eli Lilly Japan K.K. S Tanaka has received lecture fee from Bayer Japan, MSD K.K., Amgen Astellas BioPharma K.K., JMDC Inc. and Research Institute of Healthcare Data Science. He has received consultation fee from Boehringer Ingelheim and Daiichi Sankyo Co., Ltd. He has received outsourcing fee from Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Ministry of Health, Labour and Welfare of Japan, the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Novo Nordisk Pharma Ltd. He engaged in a research project of the Japan Agency for Medical Research and Development. Y Takeuchi has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mochida Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Towa Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. N Endo has received lecture honoraria from UCB Japan Co., Ltd. and Kyowa Kirin Co., Ltd. and speaker fees from Tsumura & Co. J Takada has received consulting fees and speaking fees from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Kirin Co., Ltd., Teijin Pharma Ltd., and Kaken Pharmaceutical Co., Ltd. S Ikeda has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., Hisamitsu Pharmaceutical Co., Inc., Mochida Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Towa Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co. Ltd., Viatris Inc., and UCB Japan Co., Ltd. J Iwamoto has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kaken Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Teijin Pharma Ltd., the Public Health Research Foundation, Taisho Pharmaceutical Holdings Co., Ltd., and Towa Pharmaceutical Co., Ltd. N Okimoto has received payments for lectures, including speakers\u2019 bureau fees from Asahi Kasei Pharma Corp., Amgen Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., and Teijin Pharma Ltd. Sa Tanaka has received lecture fees from Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Amgen Inc., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd. and research grants from Eli Lilly Inc., Teijin Pharma Ltd., Asahi Kasei Pharma Corp., Daiichi Sankyo Co., Ltd., and Chugai Pharmaceutical Co., Ltd","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}